Elisha M Wachman1, Marie J Hayes2, Richard Sherva3, Mark S Brown4, Hira Shrestha1, Beth A Logan5, Nicole A Heller6, David A Nielsen7, Lindsay A Farrer3. 1. Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts. 2. Graduate School of Biomedical Science and Engineering, University of Maine, Orono, Maine. 3. Department of Biomedical Genetics, Boston University School of Medicine, Boston, Massachusetts. 4. Department of Pediatrics, Eastern Maine Medical Center, Bangor, Maine. 5. Department of Transplant Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Psychology, Siena College, Loudonville, New York. 7. Department of Psychiatry, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND AND OBJECTIVES: There is significant variability in severity of neonatal abstinence syndrome (NAS) due to in utero opioid exposure. Our previous study identified single nucleotide polymorphisms (SNPs) in the prepronociceptin (PNOC) and catechol-O-methyltransferase (COMT) genes that were associated with differences in NAS outcomes. This study looks at the same SNPs in PNOC and COMT in an independent cohort in an attempt to replicate previous findings. METHODS: For the replication cohort, full-term opioid-exposed newborns and their mothers (n = 113 pairs) were studied. A DNA sample was obtained and genotyped for five SNPs in the PNOC and COMT genes. The association of each SNP with NAS outcomes (length of hospitalization, need for pharmacologic treatment, and total opioid days) was evaluated, with an experiment-wise significance level set at α < .003 and point-wise level of α < .05. SNP associations in a combined cohort of n = 199 pairs (replication cohort plus 86 pairs previously reported), were also examined. RESULTS: In the replication cohort, mothers with the COMT rs4680 G allele had infants with a reduced risk for treatment with two medications for NAS (adjusted OR = .5, p = .04), meeting point-wise significance. In the combined cohort, infants with the PNOC rs4732636 A allele had a reduced need for medication treatment (adjusted OR 2.0, p = .04); mothers with the PNOC rs351776 A allele had infants who were treated more often with two medications (adjusted OR 2.3, p = .004) with longer hospitalization by 3.3 days (p = .01). Mothers with the COMT rs740603 A allele had infants who were less often treated with any medication (adjusted OR .5, p = .02). Though all SNP associations all met point wise and clinical significance, they did not meet the experiment-wise significance threshold. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: We found differences in NAS outcomes depending on PNOC and COMT SNP genotype. This has important implications for identifying infants at risk for severe NAS who could benefit from tailored treatment regimens. Further testing in a larger sample is warranted. This has important implications for prenatal prediction and personalized treatment regimens for infants with NAS. (Am J Addict 2017;26:42-49).
BACKGROUND AND OBJECTIVES: There is significant variability in severity of neonatal abstinence syndrome (NAS) due to in utero opioid exposure. Our previous study identified single nucleotide polymorphisms (SNPs) in the prepronociceptin (PNOC) and catechol-O-methyltransferase (COMT) genes that were associated with differences in NAS outcomes. This study looks at the same SNPs in PNOC and COMT in an independent cohort in an attempt to replicate previous findings. METHODS: For the replication cohort, full-term opioid-exposed newborns and their mothers (n = 113 pairs) were studied. A DNA sample was obtained and genotyped for five SNPs in the PNOC and COMT genes. The association of each SNP with NAS outcomes (length of hospitalization, need for pharmacologic treatment, and total opioid days) was evaluated, with an experiment-wise significance level set at α < .003 and point-wise level of α < .05. SNP associations in a combined cohort of n = 199 pairs (replication cohort plus 86 pairs previously reported), were also examined. RESULTS: In the replication cohort, mothers with the COMT rs4680 G allele had infants with a reduced risk for treatment with two medications for NAS (adjusted OR = .5, p = .04), meeting point-wise significance. In the combined cohort, infants with the PNOCrs4732636 A allele had a reduced need for medication treatment (adjusted OR 2.0, p = .04); mothers with the PNOCrs351776 A allele had infants who were treated more often with two medications (adjusted OR 2.3, p = .004) with longer hospitalization by 3.3 days (p = .01). Mothers with the COMTrs740603 A allele had infants who were less often treated with any medication (adjusted OR .5, p = .02). Though all SNP associations all met point wise and clinical significance, they did not meet the experiment-wise significance threshold. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: We found differences in NAS outcomes depending on PNOC and COMT SNP genotype. This has important implications for identifying infants at risk for severe NAS who could benefit from tailored treatment regimens. Further testing in a larger sample is warranted. This has important implications for prenatal prediction and personalized treatment regimens for infants with NAS. (Am J Addict 2017;26:42-49).
Authors: Rungnapa Ittiwut; Jennifer B Listman; Chupong Ittiwut; Joseph F Cubells; Roger D Weiss; Kathleen Brady; David Oslin; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-06-08 Impact factor: 3.568
Authors: Hendrée E Jones; Sarah H Heil; Michelle Tuten; Margaret S Chisolm; Julianne M Foster; Kevin E O'Grady; Karol Kaltenbach Journal: Drug Alcohol Depend Date: 2012-12-29 Impact factor: 4.492
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: O Levran; D Londono; K O'Hara; D A Nielsen; E Peles; J Rotrosen; P Casadonte; S Linzy; M Randesi; J Ott; M Adelson; M J Kreek Journal: Genes Brain Behav Date: 2008-06-02 Impact factor: 3.449
Authors: Elisha M Wachman; Marie J Hayes; Richard Sherva; Mark S Brown; Jonathan M Davis; Lindsay A Farrer; David A Nielsen Journal: Drug Alcohol Depend Date: 2015-07-08 Impact factor: 4.492
Authors: Massroor Pourcyrous; Mohamad T Elabiad; Divya Rana; Kan P Gaston; Linda DeBaer; Ramasubbareddy Dhanireddy Journal: Pediatr Res Date: 2020-11-19 Impact factor: 3.756
Authors: Shawana Bibi; Nathan Gaddis; Eric O Johnson; Barry M Lester; Walter Kraft; Rachana Singh; Norma Terrin; Susan Adeniyi-Jones; Jonathan M Davis Journal: Pediatr Res Date: 2022-08-16 Impact factor: 3.953
Authors: Brittany L Smith; Tess A Guzman; Alexander H Brendle; Collin J Laaker; Alexis Ford; Adam R Hiltz; Junfang Zhao; Kenneth D R Setchell; Teresa M Reyes Journal: eNeuro Date: 2022-10-17
Authors: Joshua C Euteneuer; Suyog Kamatkar; Tsuyoshi Fukuda; Alexander A Vinks; Henry T Akinbi Journal: J Clin Pharmacol Date: 2018-09-11 Impact factor: 3.126
Authors: Andrew E Weller; Richard C Crist; Benjamin C Reiner; Glenn A Doyle; Wade H Berrettini Journal: Cold Spring Harb Perspect Med Date: 2021-03-01 Impact factor: 6.915